Mark Kevin, MD
Internal Medicine · Munster, INNPI 1134161169
Payments from drug & device makers
Across 90 payments — averaging $25.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$497
- Novo Nordisk$439
- Amgen$221
- Pfizer$172
- Johnson & Johnson$162
- Boehringer Ingelheim$159
- plus $612 from 18 others
What the payments were for
- Food & beverage$2,17196%
- Education$924%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 8 | $497 |
| Novo Nordisk | 12 | $439 |
| Amgen | 12 | $221 |
| Pfizer | 10 | $172 |
| Johnson & Johnson | 4 | $162 |
| Boehringer Ingelheim | 10 | $159 |
| AbbVie | 3 | $82 |
| Coloplast | 1 | $77 |
| Lilly USA, LLC | 4 | $77 |
| Sunovion Pharmaceuticals Inc. | 4 | $61 |
| Abbott | 3 | $44 |
| Dexcom, Inc. | 2 | $33 |
| Eisai Inc. | 2 | $32 |
| Mylan Specialty L.p. | 2 | $30 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Nalpropion Pharmaceuticals LLC | 2 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Avvisto Therapeutics, LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| GSK | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $11 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,263 in reported general payments places this provider in the 85th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 77 | $115,174 |
| EliquisApixaban | 93 | $112,315 |
| MounjaroTirzepatide | 71 | $103,093 |
| Enbrel SureclickEtanercept | 12 | $86,434 |
| XareltoRivaroxaban | 66 | $63,645 |
| JanuviaSitagliptin Phosphate | 47 | $63,093 |
| TradjentaLinagliptin | 47 | $43,283 |
| TrulicityDulaglutide | 35 | $41,423 |
| JardianceEmpagliflozin | 28 | $37,390 |
| FarxigaDapagliflozin Propanediol | 30 | $35,503 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $24,172 |
| Repatha SureclickEvolocumab | 14 | $20,432 |
| EntrestoSacubitril/Valsartan | 11 | $17,064 |
| InvokanaCanagliflozin | 17 | $16,472 |
| Spiriva HandihalerTiotropium Bromide | 14 | $11,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $77 | $144,516106 claims |
| Novo NordiskOzempic | $439 | $115,17477 claims |
| PfizerEliquis | $172 | $112,31593 claims |
| Boehringer IngelheimTradjenta, Jardiance | $159 | $80,67375 claims |
| Johnson & JohnsonXarelto, Invokana | $162 | $80,11783 claims |
| MerckJanuvia | $11 | $63,09347 claims |
| AstraZenecaFarxiga | $497 | $35,50330 claims |
| GSKBreo Ellipta | $12 | $24,17253 claims |
| AbbVieSynthroid | $82 | $3,74862 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Munster
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.